Thiorphan-d5
目录号 : GC48174An internal standard for the quantification of thiorphan
Cas No.:2183240-70-0
Sample solution is provided at 25 µL, 10mM.
Thiorphan-d5 is intended for use as an internal standard for the quantification of thiorphan by GC- or LC-MS. Thiorphan is an inhibitor of neprilysin (NEP; IC50 = 0.007 µM).1 It selectivity inhibits NEP over NEP2 (IC50 = 22 µM), as well as angiotensin-converting enzyme (ACE) and endothelin-converting enzyme 1 (ECE1; Kis = >0.1 and >10 µM, respectively, in cell-free assays).1,2 Thiorphan (10 µM) increases bradykinin-induced relaxation of isolated porcine coronary artery rings precontracted with potassium chloride under hypoxic, but not normoxic, conditions.3 Thiorphan reduces increases in gastric acid output induced by pentagastrin by 64% in rats when administered intracerebroventricularly at a dose of 50 µg, but not when administered intravenously at doses of 1.7 and 17 mg/kg.4 Thiorphan (2 mg/ml, i.c.v.) increases cortical levels of insoluble amyloid-β (1-40) (Aβ40) and decreases time spent in the platform quadrant in the Morris water maze, indicating impaired reference memory, in rats.5
1.Whyteside, A.R., and Turner, A.J.Human neprilysin-2 (NEP2) and NEP display distinct subcellular localisations and substrate preferencesFEBS Lett.582(16)2382-2386(2008) 2.Inguimbert, N., Coric, P., Poras, H., et al.Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP)J. Med. Chem.45(7)1477-1486(2002) 3.KrassÓi, I., Pataricza, J., and Papp, J.G.Thiorphan enhances bradykinin-induced vascular relaxation in hypoxic/hyperkalaemic porcine coronary arteryJ. Pharm. Pharmacol.55(3)339-345(2003) 4.Chicau-Chover, M., Dubrasquet, M., Chariot, J., et al.Thiorphan and acetorphan inhibit gastric secretion by a central, non-opioid mechanism in the ratEur. J. Pharmacol.154(3)247-254(1998) 5.Mouri, A., Zou, L.B., Iwata, N., et al.Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid β and impairment of learning and memoryBehav. Brain Res.168(1)83-91(2006)
Cas No. | 2183240-70-0 | SDF | |
Canonical SMILES | O=C(NCC(O)=O)C(CS)CC1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] | ||
分子式 | C12H10D5NO3S | 分子量 | 258.3 |
溶解度 | DMSO: soluble,Methanol: soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.8715 mL | 19.3573 mL | 38.7147 mL |
5 mM | 0.7743 mL | 3.8715 mL | 7.7429 mL |
10 mM | 0.3871 mL | 1.9357 mL | 3.8715 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet